Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism

被引:0
|
作者
Melania Balaş
Ioana Zosin
Christiane Maser-Gluth
Derik Hermsen
Kenko Cupisti
Matthias Schott
Sven Schinner
Wolfram T Knoefel
Werner A Scherbaum
Holger S Willenberg
机构
[1] Diabetes and Rheumatology,Department of Endocrinology
[2] University Hospital Duesseldorf,Department of Endocrinology
[3] University of Medicine and Pharmacy ‘Victor Babeş’,Department of Pharmacology
[4] University of Heidelberg,Department of General
[5] Central Institute for Clinical Chemistry and Laboratory Medicine,undefined
[6] University Hospital Duesseldorf,undefined
[7] Visceral,undefined
[8] and Pediatric Surgery,undefined
[9] University Hospital Duesseldorf,undefined
来源
Hypertension Research | 2010年 / 33卷
关键词
adrenal; aldosterone; Conn syndrome; primary aldosteronism; SUSPPUP;
D O I
暂无
中图分类号
学科分类号
摘要
It is suggested to use the aldosterone-to-renin ratio (ARR) as a first test in the screening for primary aldosteronism (PA). However, many groups rather rely on the determination of urinary tetrahydroaldosterone secretion; others calculate a ratio of urinary aldosterone to plasma renin activity. The aim of the present study was to evaluate the usefulness of different parameters of aldosterone excess in the case finding of PA. The study included 28 patients with PA and 33 subjects with essential hypertension. Clinical data, which included the hormonal parameters, serum aldosterone, plasma renin concentration, urinary free aldosterone and metabolites and serum and urinary electrolyte levels were analyzed. These indices of aldosterone excess, the ARR, serum sodium to urinary sodium to (serum potassium)2 to urinary potassium (SUSPPUP) ratio and combinations of these parameters were compared between the groups. Receiver-operating curve analysis revealed that the ARR multiplied by the SUSPPUP ratio (ARR × SUSPPUP) is the most reliable screening test, with a sensitivity of 92.3% and a specificity of 93.9% (cutoff point 199.2 (mmol l−1)−1). The combination of ARR × SUSPPUP ratio with urinary free aldosterone divided by the plasma renin concentration rendered a specificity of 100%. Less useful was the correction of urinary free aldosterone and its metabolites for sodium excretion. Although the ARR and urinary free aldosterone divided by renin are good tests in the screening for PA, the combination of ARR with SUSPPUP ratio is a better indicator of an aldosterone excess and aldosterone action in patients with ongoing antihypertensive medication. Antihypertensive drugs only marginally interfere with the SUSPPUP ratio, but they may influence the ARR, whereby the effects in PA patients seem to be negligible.
引用
收藏
页码:850 / 856
页数:6
相关论文
共 50 条
  • [1] Indicators of mineralocorticoid excess in the evaluation of primary aldosteronism
    Balas, Melania
    Zosin, Ioana
    Maser-Gluth, Christiane
    Hermsen, Derik
    Cupisti, Kenko
    Schott, Matthias
    Schinner, Sven
    Knoefel, Wolfram T.
    Scherbaum, Werner A.
    Willenberg, Holger S.
    HYPERTENSION RESEARCH, 2010, 33 (08) : 850 - 856
  • [2] THE SYNDROME OF MINERALOCORTICOID EXCESS - PRIMARY ALDOSTERONISM
    RICHARDS, V
    UTZINGER, W
    COHN, R
    MATHEWSON, C
    AMERICAN JOURNAL OF SURGERY, 1960, 100 (02): : 158 - 164
  • [3] Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity
    He, Xin
    Modi, Zubin
    Else, Tobias
    GLAND SURGERY, 2020, 9 (01) : 151 - 159
  • [4] Mineralocorticoid receptor signalling in primary aldosteronism
    Yang, Jun
    Young, Morag J.
    Cole, Timothy J.
    Fuller, Peter J.
    JOURNAL OF ENDOCRINOLOGY, 2023, 259 (01)
  • [5] Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
    Stavropoulos, Konstantinos
    Papadopoulos, Christodoulos
    Koutsampasopoulos, Konstantinos
    Lales, Georgios
    Mitas, Christos
    Doumas, Michael
    CURRENT PHARMACEUTICAL DESIGN, 2018, 24 (46) : 5508 - 5516
  • [6] 2 UNCOMMON CAUSES OF MINERALOCORTICOID EXCESS - SYNDROME OF APPARENT MINERALOCORTICOID EXCESS AND GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM
    ULICK, S
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1991, 20 (02) : 269 - 276
  • [7] PROGRESS IN PRIMARY ALDOSTERONISM Mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy
    Riester, Anna
    Reincke, Martin
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2015, 172 (01) : R23 - R30
  • [9] Mineralocorticoid receptor antagonists for primary aldosteronism - appropriate or not?
    Ragnarsson, Oskar
    Dahlqvist, Per
    Muth, Andreas
    Calissendorff, Jan
    Olsson, Tommy
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2023, 188 (03)
  • [10] Clinical, biochemical, and miRNA profile of subjects with positive screening of primary aldosteronism and nonclassic apparent mineralocorticoid excess
    Alejandra Tapia-Castillo
    Cristian A. Carvajal
    Jorge A. Pérez
    Carlos E. Fardella
    Endocrine, 2022, 77 : 380 - 391